Annovis Bio Reports Buntanetap Reduces Inflammation and Improves Neuronal Health in Alzheimer's Patients

Annovis Bio Inc. (NYSE: ANVS) announced new biomarker data showing that its investigational drug buntanetap reduces inflammation and strengthens neuronal health in Alzheimer's patients. Results from the Phase 2/3 study demonstrated significantly lower levels of key inflammatory biomarkers including IL-5, IL-6, S100A12, IFN-γ, and IGF1R in treated patients compared to those receiving placebo. The data also showed reduced neurofilament light chain levels, indicating improved cellular health and potential disease-modifying effects for Alzheimer's disease.

CEO Maria Maccechini stated that these findings confirm buntanetap's multi-targeted mechanism of action and validate earlier preclinical and clinical results. The reduction in multiple inflammatory markers suggests the drug addresses the underlying inflammatory processes associated with neurodegeneration in Alzheimer's disease. The improved neuronal integrity markers provide additional evidence that buntanetap may help protect and strengthen brain cells affected by the disease process.

The biomarker data advances confidence in buntanetap's potential to deliver meaningful therapeutic benefits for patients suffering from Alzheimer's disease. As a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer's and Parkinson's, Annovis Bio continues to build evidence supporting buntanetap's novel approach to treating these conditions. The company maintains its commitment to developing innovative therapies that improve patient outcomes and quality of life for those affected by neurodegenerative disorders. Additional information about the company and its research can be found at https://www.annovisbio.com.

These latest results contribute to the growing body of evidence supporting buntanetap's potential as a treatment for Alzheimer's disease. The reduction in inflammatory biomarkers coupled with improved neuronal health markers represents a significant step forward in understanding the drug's mechanism and potential clinical benefits. The findings suggest that buntanetap may address multiple pathological processes involved in Alzheimer's disease progression, positioning it as a promising candidate in the neurodegenerative disease treatment landscape.